NASDAQ · Biotechnology

MDGL (MDGL) Stock

$512.06 +0.33% NASDAQ: MDGL Healthcare

Valuation

MetricValue
Price$512.06
Market Cap$11.83B
P/E Ratio37.12
P/B Ratio21.63
P/S Ratio10.39
EPS (TTM)$-12.85
52-Week High$615.00
52-Week Low$276.67
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-49.35%
ROA-17.62%
ROCE-49.75%
Gross Margin93.07%
Operating Margin-27.68%
Net Margin-27.32%
Debt/Equity0.64
Current Ratio4.02

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$180.0M$958.0M
Operating Profit$-242.0M$-294.0M$-380.0M$-498.0M$-300.0M
Net Profit$-242.0M$-295.0M$-374.0M$-466.0M$-288.0M
EPS$-14.63$-17.23$-19.99$-21.90$-12.85
Op Margin———-276.4%-31.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$273.0M$363.0M$641.0M$1.0B$1.3B
Total Liabilities$77.0M$165.0M$235.0M$288.0M$657.0M
Cash$36.0M$332.0M$100.0M$100.0M$199.0M
Borrowings$1.0M$50.0M$117.0M$120.0M$354.0M

Latest News

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 GlobeNewswire · Jul 16, 2026 MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug Stocktwits · Jul 13, 2026 Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says MT Newswires · Jul 13, 2026 Sector Update: Health Care Stocks Lower Early Monday MT Newswires · Jul 13, 2026 Madrigal Pharmaceuticals Expands Rezdiffra Patent Protection With Three New Patents MT Newswires · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-184.0M$-225.0M$-324.0M$-456.0M$-190.0M
Investing Cash Flow$-5.0M$206.0M$-504.0M$-276.0M$32.0M
Financing Cash Flow$1.0M$8.0M$270.0M$338.0M$0
Net Cash Flow$-18.0M$295.0M$-232.0M$5.0M$99.0M
Free Cash Flow$-184.0M$-225.0M$-326.0M$-457.0M$-190.0M

Valuation & Return Ratios

MetricValue
PEG Ratio97.36
EV / EBITDA-36.22
FCF Yield-2.32%
Quick Ratio3.16
Interest Coverage-13.64
Return 1Y65.22%
Return 3Y153.44%
Return 5Y501.40%

Ownership

Insiders Held5.68%
Institutions Held106.99%
Institutions Float Held113.44%
Institutional HolderSharesReport Date
Baker Bros. Advisors, LP2,141,7012026-03-31
Janus Henderson Group PLC2,018,6472026-03-31
RTW Investments LP1,993,6872026-03-31
Avoro Capital Advisors LLC1,818,1812026-03-31
Blackrock Inc.1,559,9652026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABVXAbivax S.A. $136.94 +1.50% -24.37 $10.06B 0.00%
BAXBaxter International Inc. $23.18 +3.46% 11.25 $11.97B 0.88%
BMRN $60.00 -0.04% 41.31 $11.60B 0.00%
CAI $16.45 +2.17% 49.96 $4.65B 0.00%
EXELExelixis, Inc. $55.96 +0.27% 16.38 $14.07B 0.00%

About MDGL

MDGL is led by CEO William J. Sibold, employs 915 people, headquartered in West Conshohocken, US, publicly traded since 2007.

MDGL stock trades at $512.06 with a market capitalization of $11.83B. The stock is valued at a price-to-earnings (P/E) ratio of 37.12, price-to-book of 21.63, price-to-sales of 10.39. Over the past 52 weeks the stock has ranged between $276.67 and $615.00, and currently trades 16.7% below its 52-week high.

On profitability, MDGL generates a return on equity (ROE) of -49.35%, return on capital employed of -49.75%, an operating margin of -27.68%, a net profit margin of -27.32%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides